The U.K. Medicines and Healthcare products Regulatory Agency updated guidance on GLP-1 medications, including Wegovy, Ozempic and Mounjaro, to reflect a "small" risk of severe acute pancreatitis. The agency received 1,143 reports of pancreatitis among patients using semaglutide or tirzepatide, with 17 reported fatalities.
UK Warns of Pancreatitis Risk in Weight-Loss Drugs